文献速递临床免疫分子诊断

Elecsys® Anti-SARS-CoV-2免疫分析与EDI™ ELISA检测人血浆SARS-CoV-2抗体的头对头比较

Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma.
PubMed 文献 · Clin Chim Acta · 2020-05-30

本研究对全自动Elecsys® Anti-SARS-CoV-2免疫分析与EDI™酶联免疫吸附试验(ELISA)检测人血浆SARS-CoV-2抗体进行头对头比较。在64例RT-PCR确诊COVID-19患者的104份系列血样中,症状出现15-22天后Elecsys®阳性率达100%,EDI™ IgM-ELISA为94%,EDI™ IgG ELISA为100%;两种方法阳性/阴性分类一致性为90%。健康献血者和ICU患者中,Elecsys®假阳性率<1%,EDI™ ELISAs假阳性率<3%。结论提示Elecsys® assay具有高灵敏度和特异性,与EDI™ ELISAs一致性可接受。

要点

  • 症状出现15-22天后,Elecsys®检测阳性率达100%,EDI™ IgM-ELISA为94%,IgG ELISA为100%。
  • 在104份血样中,Elecsys®与EDI™ ELISAs(IgM或IgG)阳性/阴性分类一致性为90%。
  • 健康献血者和ICU患者中,Elecsys®假阳性率<1%,EDI™ ELISAs假阳性率<3%。

核心结论

  • Elecsys® assay对SARS-CoV-2抗体检测具有高灵敏度和特异性,与EDI™ ELISAs一致性可接受。

研究设计与样本

  • 研究纳入64例SARS-CoV-2 RT-PCR确诊COVID-19患者,收集不同时间点系列血样共104份。
  • 同时使用200例健康献血者和256例COVID-19暴发前ICU患者的血样进行评估。
  • 采用Elecsys® assay与EDI™ ELISAs(IgM和IgG)进行头对头比较。

主要发现

  • COVID-19患者中,阳性率随症状出现时间延长而上升,15-22天后Elecsys®为100%,EDI™ IgM-ELISA为94%,EDI™ IgG ELISA为100%。
  • 104份血样中,Elecsys®与EDI™ ELISAs(IgM或IgG)阳性/阴性分类一致性为90%。
  • 健康献血者和ICU患者中,Elecsys®假阳性率<1%,EDI™ ELISAs假阳性率<3%。

临床怎么用

  • Elecsys® assay可用于检测人血浆中SARS-CoV-2抗体,具有高灵敏度和特异性。
  • 在症状出现15-22天后,Elecsys® assay阳性率可达100%,适用于该时间窗后的抗体检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Here, we report on a head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2 immunoassay with the EDITM enzyme linked immunosorbent assays (ELISA) for the detection of SARS-CoV-2 antibodies in human plasma. METHODS: SARS-CoV-2 antibodies were measured with the Elecsys® assay and the EDITM ELISAs (IgM and IgG) in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n = 104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys® assay, of 94% for the EDITM IgM-ELISA and of 100% for the EDITM IgG ELISA. In the 104 blood samples, the agreement between positive/negative classifications of the Elecsys® assay and the EDITM ELISAs (IgM or IgG) was 90%. The false positivity rates in the healthy blood donors and the ICU patients were < 1% for the Elecsys® assay and < 3% for the EDITM ELISAs. CONCLUSIONS: Our results indicate a high sensitivity and specificity for the Elecsys® assay and an acceptable agreement with the EDITM ELISAs.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Egger M, Bundschuh C, Wiesinger K, et al. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta. 2020. PMID: 32485155. doi:10.1016/j.cca.2020.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。